In a study of prostate adenocarcinoma (PRAD), the expression of CYP2A6, CYP3A5, and CYP4B1 genes was evaluated in prostate tissue using real-time quantitative PCR (RT-qPCR). Here, CYP2A6 is linked to prostate adenocarcinoma.